Opthea (ASX:OPT) has updated investors following the recent termination of its COAST (Combination of OPT-302 with Aflibercept Study) and ShORe (Study of OPT-302 in combination with Ranibizumab) Phase 3 clinical trials. …
Latest Video
New Stories
-
The review implementation process is the next step in a negotiation
April 14, 2025 - - Latest News -
Pharmac to fund Novo Nordisk's long-acting insulin therapy
April 14, 2025 - - Latest News -
Sorry minister, but there's no world in which you kept this election commitment to newborns
April 14, 2025 - - Latest News -
API launches new B2B e-commerce platform to support its more than 4,000 customers
April 14, 2025 - - Latest News -
The 'Dispatched' Podcast - 'Week in Review' 11 April
April 11, 2025 - - Podcast -
Opthea updates investors, confirming significant staff reduction
April 10, 2025 - - Australian Biotech -
'From a patient point of view, we can provide more solutions to more health challenges'
April 10, 2025 - - Podcast